Avalo Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTX research report →
Companywww.avalotx.com
Avalo Therapeutics, Inc. , a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
- CEO
- Garry A. Neil
- IPO
- 2015
- Employees
- 23
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $183.98M
- P/E
- -3.87
- P/S
- 3118.32
- P/B
- 4.79
- EV/EBITDA
- -1.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.19%
- Op Margin
- -134164.41%
- Net Margin
- -143627.12%
- ROE
- -97.55%
- ROIC
- -89.33%
Growth & Income
- Revenue
- $59.00K · -86.62%
- Net Income
- $-78,259,000 · -122.78%
- EPS
- $-5.84 · -35.19%
- Op Income
- $-72,925,000
- FCF YoY
- -4.90%
Performance & Tape
- 52W High
- $24.27
- 52W Low
- $3.43
- 50D MA
- $15.63
- 200D MA
- $14.97
- Beta
- 0.79
- Avg Volume
- 1.42M
Get TickerSpark's AI analysis on AVTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Doyle Mittie | other | 3,000 |
| May 15, 26 | Doyle Mittie | other | 3,000 |
| May 15, 26 | Doyle Mittie | sell | 3,000 |
| May 7, 26 | Sullivan Christopher Ryan | other | 18,606 |
| May 7, 26 | Sullivan Christopher Ryan | other | 18,606 |
| May 7, 26 | Sullivan Christopher Ryan | sell | 18,606 |
| May 6, 26 | VARKI PAUL | other | 62,500 |
| May 6, 26 | VARKI PAUL | other | 12,563 |
| May 6, 26 | VARKI PAUL | other | 12,563 |
| May 6, 26 | VARKI PAUL | other | 62,500 |
Our AVTX Coverage
We haven't published any research on AVTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVTX Report →